Azelnidipine inhibits Msx2-dependent osteogenic differentiation and matrix mineralization of vascular smooth muscle cells

International Heart Journal

Volumn 53, Issue 5, 2012, Pages 331-335

  Shimizu, Takehisa ^a   Tanaka, Toru ^a   Iso, Tatsuya ^a   Kawai Kowase, Keiko ^a   Kurabayashi, Masahiko ^a  

^a GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Atherosclerosis; Calcification; Calcium channel blocker; Transcription factor

Indexed keywords

ADENOVIRUS VECTOR; ALKALINE PHOSPHATASE; AZELNIDIPINE; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL L TYPE; DILTIAZEM; NOTCH RECEPTOR; TRANSCRIPTION FACTOR MSX2; VERAPAMIL;

ALP GENE; AORTA MEDIA; ARTICLE; BLOOD VESSEL CALCIFICATION; BONE DEVELOPMENT; CELL DIFFERENTIATION; CHANNEL GATING; CONTROLLED STUDY; ENZYME ACTIVITY; GENE; GENE ACTIVATION; GENE EXPRESSION; GENE OVEREXPRESSION; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; INHIBITION KINETICS; MINERALIZATION; OSTEOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SMOOTH MUSCLE FIBER;

ALKALINE PHOSPHATASE; AZETIDINECARBOXYLIC ACID; CALCIFICATION, PHYSIOLOGIC; CALCIUM CHANNEL BLOCKERS; CELL DIFFERENTIATION; CELLS, CULTURED; DIHYDROPYRIDINES; DNA PRIMERS; GENE EXPRESSION; HOMEODOMAIN PROTEINS; HUMANS; MUSCLE, SMOOTH, VASCULAR; OSTEOGENESIS; REAL-TIME POLYMERASE CHAIN REACTION; TRANSFECTION; VASCULAR CALCIFICATION;

EID: 84867913557     PISSN: 13492365     EISSN: 13493299     Source Type: Journal    
DOI: 10.1536/ihj.53.331     Document Type: Article

References (25)

1. Lehto S, Niskanen L, Suhonen M, Rönnemma T, Laakso M. Medial artery calcification. A neglected harbinger of cardiovascular complications in non-insulin-dependent diabetes mellitus. Arterioscler Thromb Vasc Biol 1996; 16: 978-83.
2. Davies MR, Hruska KA. Pathophysiological mechanisms of vascular calcification in end-stage renal disease. Kidney Int 2001; 60: 472-9. (Review)
3. Vattikuti R, Towler DA. Osteogenic regulation of vascular calcification: an early perspective. Am J Physiol Endocrinol Metab 2004; 286: E686-96. (Review)
4. Giachelli CM. Vascular calcification mechanisms. J Am Soc Nephrol 2004; 15: 2959-64. (Review)
5. Abedin M, Tintut Y, Demer LL. Vascular calcification: mechanisms and clinical ramifications. Arterioscler Thromb Vasc Biol 2004; 24: 1161-70. (Review)
6. Iyemere VP, Proudfoot D, Weissberg PL, Shanahan CM. Vascular smooth muscle cell phenotypic plasticity and the regulation of vascular calcification. J Intern Med 2006; 260: 192-210. (Review)
7. Wilkie AO, Tang Z, Elanko N, et al. Functional haploinsufficiency of the human homeobox gene MSX2 causes defects in skull ossification. Nat Genet 2000; 24: 387-90.
8. Jabs EW, Müller U, Li X, et al. A mutation in the homeodomain of the human MSX2 gene in a family affected with autosomal dominant craniosynostosis. Cell 1993; 75: 443-50.
9. Shao JS, Cheng SL, Pingsterhaus JM, Charlton-Kachigian N, Loewy AP, Towler DA. Msx2 promotes cardiovascular calcification by activating paracrine Wnt signals. J Clin Invest 2005; 115: 1210-20.
10. Shimizu T, Tanaka T, Iso T, et al. Notch signaling induces osteogenic differentiation and mineralization of vascular smooth muscle cells: role of Msx2 gene induction via Notch-RBP-Jk signaling. Arterioscler Thromb Vasc Biol 2009; 29: 1104-11.
11. Shimizu T, Tanaka T, Iso T, et al. Notch signaling pathway enhances bone morphogenetic protein 2 (BMP2) responsiveness of Msx2 gene to induce osteogenic differentiation and mineralization of vascular smooth muscle cells. J Biol Chem 2011; 286: 19138-48.
12. Pitt B, Byington RP, Furberg CD, et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation 2000; 102: 1503-10.
13. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-97.
14. Mason RP, Marche P, Hintze TH. Novel vascular biology of thirdgeneration L-type calcium channel antagonists: ancillary actions of amlodipine. Arterioscler Thromb Vasc Biol 2003; 23: 2155-63. (Review)
15. Zhu HL, Tomoda T, Aishima M, Ito Y, Teramoto N. The actions of azelnidipine, a dihydropyridine-derivative Ca antagonist, on voltage-dependent Ba2+ currents in guinea-pig vascular smooth muscle. Br J Pharmacol 2006; 149: 786-96.
16. Ma J, Kishida S, Wang GQ, et al. Comparative effects of azelnidipine and other Ca2+-channel blockers on the induction of inducible nitric oxide synthase in vascular smooth muscle cells. J Cardiovasc Pharmacol 2006; 47: 314-21.
17. Nakamura T, Saito Y, Saito T, Kurabayashi M. Azelnidipine downregulates renal angiotensin-converting enzyme and mineralocorticoid receptor mRNA in diabetic hypertensive rats. J Pharmacol Sci 2006; 102: 239-42.
18. Doi H, Iso T, Yamazaki M, et al. HERP1 inhibits myocardin-induced vascular smooth muscle cell differentiation by interfering with SRF binding to CArG box. Arterioscler Thromb Vasc Biol 2005; 25: 2328-34.
19. Towler DA. Inorganic pyrophosphate: a paracrine regulator of vascular calcification and smooth muscle phenotype. Arterioscler Thromb Vasc Biol 2005; 25: 651-4. (Review)
20. Isaka T, Ikeda K, Takada Y, Inada Y, Tojo K, Tajima N. Azelnidipine inhibits aldosterone synthesis and secretion in human adrenocortical cell line NCI-H295R. Eur J Pharmacol 2009; 605: 49-52.
21. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022-31.
22. Yang H, Curinga G, Giachelli CM. Elevated extracellular calcium levels induce smooth muscle cell matrix mineralization in vitro. Kidney Int 2004; 66: 2293-9.
23. Stepien O, Gogusev J, Zhu DL, et al. Amlodipine inhibition of serum-, thrombin-, or fibroblast growth factor-induced vascular smooth-muscle cell proliferation. J Cardiovasc Pharmacol 1998; 31: 786-93.
24. Eickelberg O, Roth M, Mussmann R, et al. Calcium channel blockers activate the interleukin-6 gene via the transcription factors NF-IL6 and NF-kappaB in primary human vascular smooth muscle cells. Circulation 1999; 99: 2276-82.
25. Towler DA, Bidder M, Latifi T, Coleman T, Semenkovich CF. Diet-induced diabetes activates an osteogenic gene regulatory program in the aortas of low density lipoprotein receptor-deficient mice. J Biol Chem 1998; 273: 30427-34.